Business Description

Agilent Technologies, Inc. is a global provider of analytical instruments, software, services, and consumables for laboratory workflows. Headquartered in Santa Clara, California, the company primarily serves the life sciences, diagnostics, and applied chemical markets. Originally established as a spin-off from Hewlett-Packard in 1999, Agilent focuses on enabling scientific research and clinical diagnostics.

Everything on Agilent Technologies, Inc.

Revenue (FY2025) $6.95B
YoY growth +6.7%
Operating margin 21.3%
Direction Expanding
Gross margin 52.4%
Net margin 18.8%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗
Judy Gawlik Brown — Director View full profile ↗ Sue H. Rataj — Director View full profile ↗ George A. Scangos, Ph.D. — Director (Chair, Compensation Committee) View full profile ↗ Dow R. Wilson — Director (Chair, Audit and Finance Committee) View full profile ↗ Mala Anand — Director View full profile ↗ Koh Boon Hwee — Independent Chairperson of the Board View full profile ↗ Padraig McDonnell — President and Chief Executive Officer View full profile ↗ Daniel K. Podolsky, M.D. — Director View full profile ↗ Otis W. Brawley, M.D. — Director View full profile ↗ Mikael Dolsten, M.D., Ph.D. — Director View full profile ↗ Pascal Soriot — Director View full profile ↗ Bret DiMarco — Senior Vice President, Chief Legal Officer and Secretary View full profile ↗ Adam S. Elinoff — Senior Vice President and Chief Financial Officer View full profile ↗ Rodney Gonsalves — Vice President, Corporate Controllership and Chief Accounting Officer View full profile ↗ Meghan Henson — Senior Vice President, Chief Human Resources Officer View full profile ↗ Jonah Kirkwood — Senior Vice President, Chief Commercial Officer, Commercial Organization View full profile ↗ Simon May — Senior Vice President, President, Life Sciences and Diagnostics Markets Group View full profile ↗ Angelica Riemann — Senior Vice President, President, Agilent CrossLab Group View full profile ↗ Mike Zhang — Senior Vice President, President, Applied Markets Group View full profile ↗

Share Repurchase Program

Total authorized
Up to $2.0 billion (excluding excise taxes) under the 2024 repurchase program, approved by the board on May 29, 2024, effective August 1, 2024, with no fixed termination date. It succeeded the completed $2.0 billion 2023 repurchase program.
Remaining (Fiscal year ended October 31, 2025)
Approximately $1.9 billion (~$1,949 million) remaining under the 2024 repurchase program as of October 31, 2025.
Latest FY repurchased
$425 million for 3.4 million shares (excluding ~$3 million excise tax) in fiscal 2025 -- $374 million under the 2023 program and $51 million under the 2024 program.

Named Competitors

Thermo Fisher ScientificWaters CorporationDanaher CorporationBrukerShimadzu CorporationPerkinElmerRoche (Ventana Medical Systems)Twist BioscienceAB SciexLeica BiosystemsAvecia

Recent SEC Filings

2026-06-25 Entered a material agreement (+1 more) View filing ↗
2026-05-27 Reported quarterly results (+1 more) View filing ↗
2026-05-04 Leadership change (directors/officers) (+1 more) View filing ↗
2026-04-03 Change in control View filing ↗
2026-03-20 Amended charter/bylaws (+1 more) View filing ↗
2026-03-06 Leadership change (directors/officers) View filing ↗
2026-02-25 Reported quarterly results View filing ↗
2025-11-24 Reported quarterly results View filing ↗
2025-10-27 Leadership change (directors/officers) View filing ↗
2025-08-27 Reported quarterly results View filing ↗
2025-07-15 Leadership change (directors/officers) (+1 more) View filing ↗
2025-05-28 Reported quarterly results View filing ↗

More Companies

See how VectorShift works for your firm

Request Demo